Search - tctmd.com

Displaying 21 - 40 of 56

Sort: Relevancy | Date

News Conference News ESC 2022

Only Very Small Risk of Muscle Symptoms With Statins: CTT Collaboration

Michael O'Riordan

August 29, 2022

News Conference News EAS 2022

ROSE Trial: CETP Inhibitor Shows Promise as Oral Add-on for LDL-Lowering

Michael O'Riordan

May 24, 2022

News Daily News

What Can Lp(a) Add to CAC for ASCVD Risk Prediction? New Insights

Yael L. Maxwell

February 22, 2022

News Opinion Editor's Corner AHA 2021

AHA 2021 Tackles AF Triggers, Watchful Waiting in AS, Data Overload, and More

Shelley Wood

November 08, 2021

News Conference News ESC 2021

Fixed-Dose Combo Therapy Slashes CVD Risk in Primary Prevention

Michael O'Riordan

August 31, 2021

News Daily News

Vitamin D, Calcium, Other Vitamins, and Supplements Do Not Prevent CVD

Michael O'Riordan

January 25, 2021

News Conference News EAS 2020

Lp(a) and LPA Genetic Risk Score Both Predict Incident ASCVD: UK Biobank

Michael O'Riordan

October 07, 2020

News Daily News

Increased Lifetime Exposure to High LDL Cholesterol Predicts ASCVD

Michael O'Riordan

September 22, 2020

News Daily News

Cholesterol Guidelines Fail Young MI Patients Who Might Have Benefited From Statins

L.A. McKeown

August 04, 2020

News Daily News

Bempedoic Acid Safe, Lowers LDL in Hypercholesterolemia: Pooled RCT Data

Yael L. Maxwell

July 07, 2020

News Conference News ACC 2020

Pooled Inclisiran Data: Safe LDL-Lowering, Plus Hints of Fewer CVD Events

Michael O'Riordan

April 02, 2020

News Daily News

FDA Approves New Lipid-Lowering Drug, Bempedoic Acid

Shelley Wood

February 26, 2020

News Daily News

Walk and Talk: Step-Counting Devices Work Best When Paired With Doctor Consults

Yael L. Maxwell

October 10, 2019

News Conference News ESC 2019

Lifelong Exposure to Lower LDL and BP Linked With Big Reduction in CVD Events

Michael O'Riordan

September 02, 2019

News Conference News EAS 2019

Inclisiran Safe and Effective in Patients With Impaired Renal Function: ORION

Michael O'Riordan

June 04, 2019

News Conference News EAS 2019

Clear CVD Risk Reduction With PCSK9 Inhibitors, but No Mortality Effect: Meta-analysis

Michael O'Riordan

May 28, 2019

News Daily News

Quality of CAD Care Varies by Type of Medicare Coverage

Todd Neale

February 20, 2019

News Daily News

Genetic Risk Score Identifies Individuals at Heightened Risk of CAD and Other Diseases

Michael O'Riordan

August 16, 2018

News Daily News

Bariatric Surgery: Cardiometabolic Benefits Down, but Not Out, at 5 Years

Michael O'Riordan

January 18, 2018

News Daily News

It’s Official: Evolocumab Gains Claim for CVD Event Reduction

Michael O'Riordan

December 04, 2017

Advertisement

Only Very Small Risk of Muscle Symptoms With Statins: CTT Collaboration

ROSE Trial: CETP Inhibitor Shows Promise as Oral Add-on for LDL-Lowering

What Can Lp(a) Add to CAC for ASCVD Risk Prediction? New Insights

AHA 2021 Tackles AF Triggers, Watchful Waiting in AS, Data Overload, and More

Fixed-Dose Combo Therapy Slashes CVD Risk in Primary Prevention

Vitamin D, Calcium, Other Vitamins, and Supplements Do Not Prevent CVD

Lp(a) and LPA Genetic Risk Score Both Predict Incident ASCVD: UK Biobank

Increased Lifetime Exposure to High LDL Cholesterol Predicts ASCVD

Cholesterol Guidelines Fail Young MI Patients Who Might Have Benefited From Statins

Bempedoic Acid Safe, Lowers LDL in Hypercholesterolemia: Pooled RCT Data

Pooled Inclisiran Data: Safe LDL-Lowering, Plus Hints of Fewer CVD Events

FDA Approves New Lipid-Lowering Drug, Bempedoic Acid

Walk and Talk: Step-Counting Devices Work Best When Paired With Doctor Consults

Lifelong Exposure to Lower LDL and BP Linked With Big Reduction in CVD Events

Inclisiran Safe and Effective in Patients With Impaired Renal Function: ORION

Clear CVD Risk Reduction With PCSK9 Inhibitors, but No Mortality Effect: Meta-analysis

Quality of CAD Care Varies by Type of Medicare Coverage

Genetic Risk Score Identifies Individuals at Heightened Risk of CAD and Other Diseases

Bariatric Surgery: Cardiometabolic Benefits Down, but Not Out, at 5 Years

It’s Official: Evolocumab Gains Claim for CVD Event Reduction

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content